Search research articles
Contact Us
Filters
Showing results (71-80 of 126) with videos related to
Page
of 13
Sort By:
British Journal of Cancer
|
February 14, 2018
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF<sup>V600</sup> mutation-positive melanoma
Brigitte Dréno, Paolo A Ascierto, Victoria Atkinson, et al.
Journal for Immunotherapy of Cancer
|
December 28, 2020
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma
Pier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, et al.
Nature Medicine
|
June 8, 2019
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Paolo Antonio Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, et al.
Melanoma Research
|
January 3, 2020
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)
Victoria Atkinson, Shahneen Sandhu, Geke Hospers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 21, 2026
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition
Max Schlaak, Carolina Cimminiello, Jacopo Pigozzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 3, 2019
Reply to E. Hindié and K.R. Hess
Georgina V Long, Reinhard Dummer, Dirk Schadendorf, et al.
The Lancet. Oncology
|
April 1, 2019
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF<sup>V600E</sup> or BRAF<sup>V600K</sup> mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial
Dirk Schadendorf, Axel Hauschild, Mario Santinami, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 23, 2018
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600-Mutant Stage III Melanoma
Axel Hauschild, Reinhard Dummer, Dirk Schadendorf, et al.
Nature Medicine
|
October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
Reinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.
The New England Journal of Medicine
|
September 12, 2017
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Georgina V Long, Axel Hauschild, Mario Santinami, et al.
Page
of 13
Search research articles
Search
Showing results (71-80 of 126) with videos related to
Sort By:
Page
of 13
British Journal of Cancer
|
February 14, 2018
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF<sup>V600</sup> mutation-positive melanoma
Brigitte Dréno, Paolo A Ascierto, Victoria Atkinson, et al.
Journal for Immunotherapy of Cancer
|
December 28, 2020
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma
Pier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, et al.
Nature Medicine
|
June 8, 2019
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Paolo Antonio Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, et al.
Melanoma Research
|
January 3, 2020
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)
Victoria Atkinson, Shahneen Sandhu, Geke Hospers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 21, 2026
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition
Max Schlaak, Carolina Cimminiello, Jacopo Pigozzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 3, 2019
Reply to E. Hindié and K.R. Hess
Georgina V Long, Reinhard Dummer, Dirk Schadendorf, et al.
The Lancet. Oncology
|
April 1, 2019
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF<sup>V600E</sup> or BRAF<sup>V600K</sup> mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial
Dirk Schadendorf, Axel Hauschild, Mario Santinami, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 23, 2018
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600-Mutant Stage III Melanoma
Axel Hauschild, Reinhard Dummer, Dirk Schadendorf, et al.
Nature Medicine
|
October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
Reinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.
The New England Journal of Medicine
|
September 12, 2017
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Georgina V Long, Axel Hauschild, Mario Santinami, et al.
Page
of 13